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ABSTRACT
Background: Percutaneous revascularization in diabetic is 
frequent and the use of drug-eluting stents (DES) is desir-
able, since they reduce restenosis and the need for repeat 
revascularization. The objective of this study was to compare 
the long-term outcomes of diabetic patients treated with and 
without DES. Methods: A consecutive cohort of diabetic patients 
undergoing percutaneous coronary intervention (PCI) between 
January 2009 and December 2012 in a public tertiary hospital 
was prospectively followed-up. Results: Nine hundred and 
thirty-nine diabetic patients (38.3%) treated with DES and 580 
(61.7%) treated with bare metal stents (BMS) were evaluated. 
The rate of major adverse cardiac events (MACE) in 12.6 ± 
3.4 months was greater in the BMS group (9.5% vs. 14.8%; 
RR, 1.56; 95% CI, 1.07-2.27; P = 0.02), as well as death 
(2.8% vs. 6.7%; RR, 2.41; 95% CI, 1.22-4.77; P  <  0.01), 
and target vessel revascularization (3.9% vs. 7.2%; RR, 1.85; 
95% CI, 1.03-3.35; P = 0.04). There were no differences in 
the incidence of myocardial infarction (1.7% vs. 0.5%; RR, 
0.30; 95% CI, 0.07-1.23; P = 0.08) or stroke (1.1% vs. 0.2%; 
RR, 0.15; 95% CI, 0.01-1.37; P = 0.07). Multivariate analysis 
indicated that chronic kidney disease (RR, 2.05; 95% CI, 1.40-
2.98; P < 0.01) and acute coronary syndrome (RR, 2.08; 95% 
CI 1.42-3.02; P < 0.01) were the only independent predictors 
of MACE. Conclusions: In non-selected diabetic patients the 
long-term clinical outcome was worse for patients treated 
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RESUMO
Evolução Clínica de Pacientes Diabéticos Tratados 
por Intervenção Coronária Percutânea Utilizando 
Stents Com e Sem Eluição de Fármacos
Introdução: A revascularização percutânea de diabéticos é 
frequente e a utilização de stents farmacológicos (SF) é de-
sejável, pois estes reduzem a reestenose e a necessidade de 
nova revascularização. O objetivo desse estudo foi comparar 
os resultados clínicos de longo prazo entre diabéticos tratados 
com e sem SF. Métodos: Analisou-se uma coorte consecutiva 
de diabéticos submetidos à intervenção coronária percutânea 
(ICP) entre janeiro de 2009 e dezembro de 2012, em hospital 
terciário da rede pública. Esses pacientes foram acompanha-
dos prospectivamente. Resultados: Avaliamos 939 diabéticos, 
sendo 359 (38,3%) tratados com SF e 580 (61,7%) tratados 
com stents não farmacológicos (SNF). A taxa de eventos car-
diovasculares adversos maiores (ECAM) em 12,6 ± 3,4 meses 
foi maior no grupo SNF (9,5% vs. 14,8%; risco relativo – RR = 
1,56; intervalo de confiança de 95% – IC 95% 1,07-2,27; P = 
0,02), assim como o óbito (2,8% vs. 6,7%; RR = 2,41; IC 95% 
1,22-4,77; P < 0,01) e a revascularização do vaso alvo (3,9% 
vs. 7,2%; RR = 1,85; IC 95% 1,03-3,35; P = 0,04). Não foram 
observadas diferenças na incidência de infarto do miocárdio 
(1,7% vs. 0,5%; RR = 0,30; IC 95% 0,07-1,23; P = 0,08) ou 
acidente vascular encefálico (1,1% vs. 0,2%; RR = 0,15; IC 
95% 0,01-1,37; P = 0,07). A análise multivariada revelou que a 
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cost than that of BMS, could occur in the treatment 
of subgroups with more complex coronary anatomy, 
such as diabetics.
Thus, this study aimed to investigate the late clini-
cal outcome in diabetic patients treated with PCI, with 
and without DES implantation.
METHODS
From January 2009 to December 2011, a consecu-
tive cohort of diabetic patients undergoing PCI in the 
Instituto Dante Pazzanese de Cardiologia, São Paulo, 
Brazil, a tertiary public hospital with extensive expe-
rience in percutaneous procedures, was analyzed. 
The primary objective was to compare the rate of 
major adverse cardiovascular events (MACE), defined 
as death, stroke, AMI, and target vessel revasculariza-
tion (TVR) in diabetic patients treated with and without 
DES. The secondary objective was to evaluate the rates 
of occurrence of each clinical event isolated in both 
groups, as well as to identify possible independent 
predictors of MACE.
Definitions
Diabetes mellitus was diagnosed according to the 
criteria of the American Diabetes Association: presence 
of fasting glucose values ≥ 126 mg/dL, or glycated he-
moglobin ≥ 6.5%, or glucose ≥ 200 mg two hours after 
a glucose overload. Death was defined as any death, 
regardless of cause, and cardiac death as a death sec-
ondary to immediate cardiac causes (AMI, heart failure, 
and fatal arrhythmia), in addition to unwitnessed deaths 
and/or deaths due to unknown causes.
The diagnosis of AMI was established when peripro-
cedural elevation of CK-MB >  3 times the upper limit 
of normal was observed, in association with symptoms 
indicative of myocardial ischemia or with the presence 
of new Q waves on ECG after the procedure, or with 
changes in regional contractility on imaging exams dur-
ing the in-hospital stay. Conversely, the occurrence of 
AMI after discharge was considered in cases of a rise 
and fall of troponin or CK-MB levels, in association 
with BMS. After adjusting for confounding variables, the use 
of DES was not an independent predictor of reduced MACE.
 
 
 
 
DESCRIPTORS: Percutaneous coronary intervention. Diabetes 
mellitus. Drug-eluting stents. Coronary artery disease.
doença renal crônica (RR = 2,05; IC 95% 1,40-2,98; P < 0,01) 
e a síndrome coronária aguda (RR = 2,08; IC 95% 1,42-3,02; 
P < 0,01) foram os únicos preditores independentes de ECAM. 
Conclusões: Em pacientes diabéticos não selecionados, a evo-
lução clínica tardia foi pior para os tratados com SNF. Após o 
ajuste das variáveis de confusão, o uso de SF não se mostrou 
preditor independente da redução de ECAM.
Descritores: Intervenção coronária percutânea. Diabetes melli-
tus. Stents farmacológicos. Doença da artéria coronariana.
C oronary artery disease (CAD) accounts for approxi-mately 75% of cardiovascular deaths in diabetics.1 A considerable number of these patients undergo 
percutaneous coronary intervention (PCI), whether in 
the presence of acute conditions or for the treatment 
of the stable disease; currently, diabetics represent 
approximately 30% of those percutaneously revascu-
larized patients.2
In these patients, CAD has peculiar characteristics, 
either due to the association of comorbidities, which 
increase the clinical risk, or to the presence of more 
extensive and complex atherosclerotic disease, with 
smaller vessels and a greater propensity to thrombosis. 
Specifically regarding PCI, this subgroup has a greater 
tendency to coronary restenosis after stent implanta-
tion, and a higher incidence of other adverse cardiac 
events in the late evolution, such as death and acute 
myocardial infarction (AMI).3-5
In turn, drug-eluting stents (DES) have proven their 
effectiveness in reducing restenosis and the need for 
additional revascularization procedures when compared 
to bare metal stents (BMS) in both the overall population 
and in the diabetic subgroup.6,7 In these latter patients, 
drug-eluting prostheses have also been widely investi-
gated, demonstrating high success rates, low rates of 
acute complications, and significant reduction of new 
revascularizations when compared to BMS.8
However, the results related to major cardiovascular 
safety outcomes, such as death, AMI, and stroke in the 
medium- to long-term are still contradictory.7-9 Some 
international registries have observed reduction of mor-
tality and AMI in favor of DES in diabetic patients, in 
both early and late stages10 – benefits not observed in 
other series.11,12 More recent randomized trials compar-
ing these prostheses with CABG in multivessel diabetics 
also failed to demonstrate favorable results for DES.13,14
In Brazil, where the majority of CAD patients are 
treated in the public health network, subject to curtail-
ment of funds provided by the Brazilian Unified Health 
System (Sistema Único de Saúde – SUS), the acquisition 
of DES for universal use is impractical. In this context, 
the availability of these devices, with a much higher 
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with typical ischemic symptoms or with electrocardio-
graphic changes (new Q waves/ST segment elevation 
or lowering), or with a need for urgent revasculariza-
tion, or finally, in face of anatomopathological findings 
consistent with acute ischemia.
Stroke was defined as the occurrence of cerebral 
infarction (ischemic stroke) or subarachnoid and brain 
hemorrhage (hemorrhagic stroke), with symptoms per-
sisting > 24 hours or that resulted in death < 24 hours. 
TVR was defined as the performance of a new 
percutaneous or surgical procedure after discharge to 
treat the target vessel, in the presence of angina or of 
a clinical equivalent of ischemia, or in the presence 
of functional tests with abnormal results.
Stent thrombosis was defined according to the 
criteria of the Academic Research Consortium (ARC) 
as definite if confirmed by angiographic (Trombolysis 
in Myocardial Infarction [TIMI] flow = 0 with stent 
occlusion by thrombus or TIMI flow 1, 2, or 3 and 
presence of thrombus) or anatomopathological find-
ings; or as probable, defined as any unexplained death 
within the first 30 days after PCI or any AMI related 
to the target vessel without angiographic confirmation 
and in the absence of any other causes.15
Procedure
The percutaneous procedure was performed accord-
ing to the standard practice recommended by national 
and international guidelines.16,17 The choice of access 
route (femoral or radial) was at the discretion of the 
surgeon, as well as the use of glycoprotein IIb/IIIa. 
Dual antiplatelet therapy consisted of acetylsali-
cylic acid at a dose of 100 mg/day in patients with 
chronic use, and 300 mg (loading dose) in previously 
untreated patients. Clopidogrel was the P2Y12 inhibi-
tor most frequently used, at loading doses of 300 to 
600  mg before the procedure and, subsequently, 75 
mg/day combined with acetylsalicylic acid 100 mg/
day for one year.
The decision to use DES was at the surgeon’s discre-
tion and subject to the availability of the device at the 
time of the trial, considering the following scenarios: 
vessels ≤ 2.5 mm, lesions > 20 mm and in-stent reste-
nosis; expectation of non-adherence to dual antiplatelet 
therapy at one year; presence of hemorrhagic diathesis, 
or of hematologic diseases, or prior and recent history 
(< six months) of digestive, urological, or other bleeding 
that could prevent the use of dual antiplatelet therapy 
for the recommended time.
Clinical follow-up
The clinical follow-up was prospective, and 
conducted by clinical visits with review of records, 
since this tertiary hospital has an outpatient setting 
for monitoring patients undergoing PCI. Contacts by 
phone, email, telegram, or reports from physicians who 
referred patients to this service were used.
Statistical analysis
Continuous variables were analyzed as means ± 
standard deviations and compared using the Mann-
Whitney test. Categorical variables were compared using 
the chi-squared or Fisher’s exact test, when appropriate.
Analysis of survival free of event was obtained using 
Kaplan-Meier curves, and comparisons were performed 
using the log-rank method.
Multivariate regression models were derived from 
Cox for MACE, and the variables considered for in-
clusion in the multivariate models were age, gender, 
insulin use, chronic renal failure (CRF), acute coronary 
syndrome (ACS), prior PCI, number of vessels treated, 
use of periprocedural DES, and AMI. The significance 
level for permanence in the model was adjusted to 0.01. 
To perform the analysis, the SPSS, version 20.0, 
was used. P-values < 0.05 were considered significant.
RESULTS
939 consecutive diabetic patients were analyzed; 
359 patients (38.3%) were treated with DES and 580 
patients (61.7%) with BMS. Mean follow-up in both 
groups was 12.9 ± 3.6 months (1-13 months) and 12.4 
± 2.5 months (1-14 months), respectively, and 80% of 
patients had a minimum follow-up of one year.
Demographic and clinical characteristics of these 
patients revealed a higher proportion of patients with 
risk factors for atherosclerosis, previous AMI, heart 
failure, previous PCI, and stable clinical status in dia-
betic patients treated with DES, whereas patients with 
chronic kidney disease and ACS were more frequent in 
the group treated with BMS. Regarding the pharmaco-
logical treatment before the procedure, patients treated 
with DES most often used beta-blockers, statins, and 
insulin (Table 1).
In the DES group, the left anterior descending 
artery was the most frequently target vessel (50.7%), 
and multivessel PCI was more frequent (25.3% vs. 
5.7%; P < 0.01), resulting in a ratio target vessel per 
patient/stent per patient also significantly higher in this 
group. A significantly higher percentage of bifurcation 
injuries and restenotic lesions was observed in patients 
treated with DES (Table 2). Zotarolimus- (65%), siroli-
mus- (31%), paclitaxel- (2.5%), and novolimus (1.5%) 
-eluting stents were used.
In relation to in-hospital outcomes, the clinical 
success rate of PCI was similar in both groups (97.2% 
vs. 95.6%; P = 0.22), with no differences in the oc-
currence of death (0% vs. 0.7%; P = 0.30) and stroke 
(0% vs. 0.2; P = 0.99). The group of patients treated 
with DES showed a higher incidence of elevation of 
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periprocedural myocardial injury markers when compared 
to those treated with BMS (8.6% vs. 4.0%; P < 0.01).
In a clinical follow-up of 12.6 ± 3.4 months, the 
rate of MACE was higher in the group receiving BMS 
(9.5% vs. 14.8%; RR = 1.56; 95% CI: 1.07-2.27; 
P = 0.01). Death by the end of clinical follow-up was 
also higher in the BMS group (2.8% vs. 6.7%; RR = 
2.41; 95% CI: 1.22-4.77; P < 0.01), as well as death 
of cardiac origin (1.7% vs. 3.7%; RR = 2.78; 95% CI: 
1.16-6.68; P = 0.01) and TVR (3.9% vs. 7.2%; RR = 
1.85; 95% CI: 1.03-3.35; P  =  0.03). Moreover, there 
TABLE 1 
Clinical and demographic characteristics of patients
Characteristics 
DES  
(n = 359)
BMS  
(n = 580) P-value
Age, years 63.0 ± 10.6 63.2 ± 10.5 0.80
Female, n (%) 145 (40.4) 219 (37.8) 0.42
Hypertension, n (%) 337 (93.9) 533 (91.9) 0.30
Dyslipidemia, n (%) 314 (87.5) 453 (78.1) < 0.01
Smoking, n (%) 204 (56.8) 62 (10.7) < 0.01
Prior PCI, n (%) 104 (29.0) 64 (11.0) < 0.01
Previous CABG, n (%) 35 (9.7) 88(11.0) 0.17
Prior AMI, n (%) 163 (45.4) 224 (38.6) 0.04
Prior stroke or TIA, n (%) 13 (3.6) 18 (3.1) 0.70
Family history of CAD,  
n (%) 
73 (20.3) 52 (9.0) < 0.01
COPD, n (%) 4 (1.1) 10 (1.7) 0.58
CRF not requiring dialysis, 
n (%) 
27 (7.5) 188 (32.4) < 0.01
POAD, n (%) 16 (4.5) 16 (2.8) 0.19
Heart failure, n (%) 127 (35.4) 9 (1.6) < 0.01
Clinical status, n (%) < 0.01
 Acute coronary syndrome 36 (10.0) 174 (30.0)
 Stable angina 218 (60.7) 268 (46.2)
 Asymptomatic 105 (29.2) 138 (23.8)
 Pharmacological  
treatment, n (%) 
 Insulin 106 (29.5) 58 (10.0) < 0.01
 Oral hypoglycaemic 313 (87.2) 520 (89.7) 0.24
 Acetylsalicylic acid 357 (99.4) 568 (97.9) 0.09
 Statins 357 (99.4) 537 (92.4) < 0.01
 ACEI/BRA 336 (93.6) 536 (92.4) 0.51
 Beta blockers 343 (95.5) 477 (80.5) < 0.01
DES = drug-eluting stents; BMS = bare metal stents; PCI = percutaneous 
coronary intervention; CABG = coronary artery bypass graft surgery; 
AMI = acute myocardial infarction; TIA = transient ischemic attack; 
CAD = coronary artery disease; COPD = chronic obstructive pulmonary 
disease; CRF = chronic renal failure; POAD = peripheral obstructive 
arterial disease; ACEI/ARB = angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers.
TABLE 2 
Angiographic and procedural characteristics 
Characteristics 
DES  
(n = 359)
BMS  
(n = 580) P-value
Target vessels, n (%) < 0.01
  Left anterior descending 
artery
182 (50.7) 186 (32.1)
 Left circumflex artery 64 (17.8) 103 (17.7)
 Right coronary artery 61 (17) 200 (34.5)
 Left main coronary artery 1 (0.3) 9 (1.6)
Saphenous graft, n (%) 14 (3.9) 37 (6.4) 0.10
Bifurcation, n (%) 79 (22) 57 (9.8) < 0.01
Total occlusion, n (%) 10 (2.7) 17 (2.9) 0.89
Restenosis, n (%) 61 (17) 15 (2.6) < 0.01
Number of vessels treated 
per patient 
1.5 ± 0.22 1.0 ± 0.50 < 0.01
Treatment of two or more 
vessels, n (%) 
91 (25.3) 33 (5.7) < 0.01
Number of stents per 
patient 
1.48 ± 0.5 1.07 ± 0.4 < 0.01
Stent caliber, mm 2.90 ± 4.2 3.10 ± 4.3 0.11
Stent length, mm 19.6 ± 9.3 20.5 ± 6.6 0.09
DES = drug-eluting stents; BMS = bare metal stents.
were no significant differences between the two groups 
in the incidence of AMI (1.7% vs. 0.5%; RR = 0.30; 
95% CI: 0.07-1.23; P = 0.07) and stroke (1.1% vs. 
0.2%; RR = 0.15; 95% CI: 0.01-1.37; P = 0.07) in the 
same trial period (Table 3).
The results of the Kaplan Meier curves regarding 
survival free of MACE, death, death of cardiac origin, 
and TVR are detailed in Figure 1, revealing significant 
differences in favor of DES. 
In relation to definite or probable stent thrombosis, 
this complication had a very low incidence in both 
groups (0.83% vs. 0%; P = 0.06) during the relatively 
short follow-up period.
A multivariate analysis of pre-specified variables 
identified only chronic renal disease (CRD) (RR = 2.05; 
95% CI: 1.40-2.98; P < 0.01) and ACS (RR = 2.08; 
95% CI: 1.42-3.02; P < 0.01) as independent predic-
tors for occurrence of MACE in the late evolution of 
diabetes (Table 4). The use of DES was shown to be a 
predictor of MACE in this group (RR = 1.35; 95% CI: 
0.87-2.10; P = 0.17).
DISCUSSION
In the present study, which included a cohort of 
untreated, non-selected diabetic patients for PCI in a 
tertiary public hospital, a reduction of MACE, death, 
death due to a cardiac cause, and TVR in the group 
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treated with DES was observed. However, after adjust-
ing for confounding variables, the use of DES did not 
modify the occurrence of combined adverse events. 
Chronic renal disease and ACS were the only prespeci-
fied variables predictors of poorer clinical outcome.
Currently, the technological development of materials 
available for the completion of PCI, together with the 
vast experience of the surgeons in the management of 
high-risk patients and the availability of DES, allowed 
for the expansion of indications for percutaneous 
TABLE 3 
Cardiovascular events at the end of one year
Event
DES
(n = 359)
BMS
(n = 580) RR 95% CI P-value
MACE, n (%) 34 (9.5) 86 (14.8) 1.56 1.07-2.27 0.01
Death, n (%) 10 (2.8) 39 (6.7) 2.41 1.22-4.77 < 0.01
Cardiac death, n (%) 6 (1.7) 27 (3.7) 2.78 1.16-6.68 0.01
Stroke, n (%) 4 (1.1) 1 (0.2) 0.15 0.01-1.37 0.07
AMI, n (%) 6 (1.7) 3 (0.5) 0.3 0.07-1.23 0.07
TVR, n (%) 14 (3.9) 42 (7.2) 1.85 1.03-3.35 0.03
DES = drug-eluting stents; BMS = bare metal stents; RR = relative risk; 95% CI = 95% confidence interval; MACE = main adverse 
cardiovascular events; AMI = acute myocardial infarction; TVR = target vessel revascularization.
Figure – Curves: survival free of major adverse cardiovascular events (A); survival (B); survival free of cardiac death (C); survival free from target 
vessel revascularization (D). DES = drug-eluting stent; BMS = bare metal stent.
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treatment, including patients with CAD of high clini-
cal and anatomical complexity, such as diabetics.16,17
In the present study, it was observed that diabetics 
treated with DES corroborate this scenario, in that these 
patients presented more challenging angiographic char-
acteristics, often involving the treatment of left anterior 
descending artery (with a greater area of myocardium 
at risk for ischemia), lesions located in bifurcations, 
and coronary restenoses. Acknowledging the complexity 
of the lesions treated, a greater number of vessels was 
approached, resulting in a significantly higher ratio of 
vessels treated per number of stents in the group of 
diabetics revascularized with DES. Such features require 
the use of more efficient prostheses, with elution of 
drugs that effectively inhibit neointimal proliferation, 
in order to reduce the recurrence of obstructions due 
to coronary restenosis, and, hence, the need for new 
revascularizations in patients already predisposed to 
these events.
In the literature, several trials comparing the use 
of DES vs. BMS in diabetic and nondiabetic patients 
have clearly demonstrated the superiority of the former 
device in significantly reducing coronary restenosis and, 
therefore, in a new approach to recurrent lesions, reduc-
ing the exposure of patients to the inherent risks of a 
new procedure, whether percutaneous or surgical.7,11,12
It is also interesting to note, in the present popula-
tion, the greater proportion of patients using insulin in 
the DES group (29.5% vs. 10.0%; P < 0.01), indicating 
a greater severity and duration of diabetes. It is known 
that, in general, these patients may experience a more 
diffuse atherosclerotic disease and an intense inflam-
matory process of the coronary arteries and vascular 
beds in general, which result in greater predisposition 
to restenosis, arterial thrombosis, and AMI.18-20 A recent 
brazilian publication21 investigated in-hospital outcomes 
of nearly 2,000 diabetic patients from the Angiocardio 
Registry undergoing PCI, divided among those treated 
with insulin (21%) and those using oral hypoglycemic 
agents. The researchers found that, despite the higher 
percentage of women and of chronic kidney disease in 
the insulin subgroup, the major cardiovascular outcomes 
were similar in both groups, and the insulin treatment 
was not an independent predictor for the occurrence 
of adverse events in the in-hospital phase.
A register held by the National Heart, Lung, and 
Blood Institute in 2008, involving over 2,500 diabetic 
patients with and without insulin use treated with DES 
and BMS, revealed that the use of DES reduced the risk 
of repeat revascularization and of safety outcomes such 
as death and AMI. However, the reduction in mortality 
and in AMI was restricted to diabetics not treated with 
insulin.21 It is noteworthy that, in the present study, the 
use of insulin was not a predictor of adverse cardio-
vascular events in the long-term.
Regarding in-hospital results, the present findings 
demonstrated equivalent procedural success rates be-
tween the two types of stents, as well as the rates of 
occurrence of death and stroke, confirming the safety 
and efficacy of DES in the earliest phase after PCI. 
The higher incidence of elevated markers of peri-PCI 
myocardial injury probably relates to the greater ana-
tomical complexity of the lesions treated in the DES 
subgroup, with a larger number of approached vessels 
and of implanted stents.
Regarding stent thrombosis (definite or probable, ac-
cording to ARC criteria), this occurrence was very low in 
both groups (0.83% vs. 0%) in a follow-up period of 12.6 
± 3.4 months. These results are similar to the ESSENCE-
DIABETES II trial conducted by Park et al.,22 who observed 
rates of subacute and late thrombosis in diabetic patients 
undergoing implantation of zotarolimus- and sirolimus-
eluting stents < 1% after 12 months of evolution.
Regarding the primary outcome of the trial, it 
was demonstrated that the occurrence of MACE was 
significantly lower in diabetic patients treated with 
DES, and the same occurred with death due to a 
cardiac cause and TVR. At first glance, these results 
appear to demonstrate that the use of DES in diabetics 
is related to better clinical outcome in the long-term, 
which requires caution in interpreting the data. When 
comparing the present results to those of other trials, 
it was observed that the majority of them presented 
no significant reduction in mortality or in other major 
cardiovascular outcomes in patients treated with DES, 
whether or not they were diabetic.23,24
TABLE 4 
Predictors of major adverse cardiovascular  
events in diabetic patients
RR 95% CI P-value
Age 1.10 0.99-1.03 0.08
Gender 1.00 0.69-1.45 0.97
Insulin use 0.96 0.60-1.54 0.87
Chronic renal 
failure 
2.05 1.40-2.98 < 0.01
Acute coronary 
syndrome 
2.08 1.42-3.02 < 0.01
Previous PCI 0.80 0.48-1.33 0.40
Number of vessels 
treated 
0.74 0.44-1.25 0.27
Heart failure 0.61 0.32-1.13 0.11
DES use 1.35 0.87-2.10 0.17
Periprocedural AMI 1.50 0.80-2.92 0.19
RR = relative risk; 95% CI = 95% confidence interval; PCI = 
percutaneous coronary intervention; DES = drug-eluting stent; 
AMI = acute myocardial infarction.
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Some trials have observed a reduction of stent 
thrombosis and AMI, but without a consistent reduc-
tion in the mortality rates with the use of this type of 
prosthesis, even with the second- or third-generation, 
so called due to their new metal platforms, more bio-
compatible and less thrombogenic polymers, and drugs 
with higher power of neointimal inhibition.8,25
Other observational trials and international registries, 
involving large numbers of diabetic and nondiabetic 
patients treated with DES, observed a reduction of 
ominous outcomes such as death and AMI, as well as 
in the rates of new revascularizations.10,26,27 However, 
these results deserve reflection and must be viewed 
with caution, due to a possible selection bias and the 
relatively short duration of the clinical follow-up. In the 
present study, for instance, the multivariate analysis of 
the predictors for the occurrence of MACE took into 
consideration chronic renal disease and ACS, a fact fully 
demonstrated in the literature.28 Coincidentally, these 
variables were significantly more present in patients 
treated with BMS, which was a disadvantage for this 
group and could explain the better results obtained in 
patients undergoing DES implantation. After adjustment 
of the multivariate analysis, no significant differences 
were observed in the rates of MACE between patients 
treated with and without DES at the end of one year 
of clinical follow-up (RR = 1.35; 95% CI: 0.87-2.10; 
P = 0.17). 
The choice of BMS implantation in diabetic patients 
with ACS and renal failure – without doubt, patients at 
high risk for adverse events – can be questioned. Some 
possible explanations are: (1) DES are not routinely 
available in most public hospitals linked to the SUS; 
(2 ) the safety and efficacy of BMS for the treatment 
of patients with acute ischemic conditions, requiring 
urgent or emergent PCI, is equivalent to the safety and 
efficacy for DES, since in such cases the priority is 
the treatment of the culprit lesion, in order to reduce 
acutely events such as death and AMI; (3) in patients 
with ACS, the option of BMS use may be preferable, 
due to issues related to a lack of detailed knowledge 
of the patient’s clinical history in terms of adherence 
to dual antiplatelet therapy, or even to the necessity of 
an early discontinuation of this therapy, due to non-
cardiac comorbidities; and (4) in chronic renal patients, 
the use of BMS can be defended in view of a potential 
need for invasive non-cardiac procedures, such as the 
implantation of catheters or performing arteriovenous 
fistulas for dialysis and the possibility of a kidney trans-
plant – situations in which a dual antiplatelet therapy 
may predispose to major bleeding.
Limitations
This was a nonrandomized trial, and therefore 
subject to selection bias; the follow-up period was 
relatively short for the analysis of the real differences 
in the occurrence of adverse cardiovascular events in 
diabetic patients; and no information regarding adhesion 
and duration of dual antiplatelet therapy was obtained, 
factors that could affect the incidence of adverse events, 
especially in patients treated with DES and in those 
with pre-PCI ACS.
CONCLUSIONS
In a population consisting of unselected diabetic 
patients treated by PCI, the use of DES was associated 
with significantly lower rates of major cardiovascular 
outcomes compared to BMS. However, after adjusting 
for confounding variables, the use of DES was not an 
independent predictor of major adverse cardiovascular 
events in the long-term.
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